This time I’m going to focus on one company and its view on pharma’s digital commercial strategy ... was the high level of uncertainty about its effects. In March 2020 Pfizer began ...

Pfizer used the investor event to formally introduce its new business division dedicated to cancer research and to lay out a long-term strategy for it through the end of the decade. That oncology ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Collis, David J. "Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)." Harvard Business School Teaching Note 713-450, March 2013.

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.

A potential combination with AstraZeneca aligns with Pfizer’s current structure and fully supports its existing strategy to build world-class ... heritage as an innovation-driven biopharmaceutical ...

BMO Capital markets analyst Evan Seigerman said Pfizer's forecast is already conservative, and with COVID products no longer seen as a core business, investor reaction to lower volumes could be muted.

Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership ... When asked about the visibility into the business, Albert Bourla added that the main ...

Pfizer had largely honed in on breast and prostate cancers, cancer chief Andy Schmeltz told Business Insider earlier ... Read more: Pfizer has a new strategy for fighting cancer that could ...